You are here: Industry Insights > Ovarian cancer

News List

Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals prnasia
December 09, 2020
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian cancer (NCT02903771).
Lynparza scores two new EU approvals pharmatimes
November 09, 2020
AstraZeneca and MSD's immunotherapy Lynparza (olaparib) has scored two new approvals in the European Union.
Blood test more predictive of ovarian cancer than ‘previously thought’ pharmatimes
October 30, 2020
An already available blood test can better predict ovarian cancer than was previously thought, according to research published in PLOS Medicine yesterday.
Lynparza scores long-term benefit data in BRCA-mutated ovarian cancer pharmatimes
September 22, 2020
AstraZeneca and MSD’s (Merck) PARP inhibitor Lynparza has demonstrated long-term progression-free survival (PFS) benefit in BRCA-mutated advanced ovarian cancer.
Celsion Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer americanpharmaceuticalreview
August 03, 2020
Celsion announced the randomization of the first two patients in the Phase II portion of the Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer.
Tecentriq misses mark in ovarian cancer trial pharmatimes
July 15, 2020
Roche and Genentech's Tecentriq (atezolizumab) has failed to hit its primary goal in a late stage trial involving patients with newly diagnosed advanced stage ovarian cancer.
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer pharmaceutical-business-review
June 17, 2020
Clovis Oncology announced the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP) ...
Lynparza, Bevacizumab Combination Approved for HRD-Positive Advanced Ovarian Cancer in the US americanpharmaceuticalreview
May 15, 2020
AstraZeneca and Merck announced that Lynparza (olaparib) in combination with bevacizumab has been approved in the US for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
US nod for Lynparza in HRD-positive advanced ovarian cancer pharmatimes
May 12, 2020
AstraZeneca and MSD's Lynparza (olaparib) has been cleared in the US for use as a first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer.
Cediranib trips up in Lynparza combo ovarian cancer trial pharmatimes
March 16, 2020
AstraZeneca and MSD have reported results from the Phase III GY004 trial, in which potential new medicine cediranib, when added to Lynparza (olaparib), did not meet the trial’s primary endpoint.

Previous page 1 2 3 4 5 6 7 8 Next page